论文部分内容阅读
目的:观察冠心通络胶囊联合双联抗血小板药物防治冠心病PCI术后再狭窄的临床疗效。方法:将我院心血管内科收治符合纳入标准的68例冠心病行PCI术患者作为观察对象,随机将其分为治疗组与对照组,每组各34例,对照组予西医常规结合双联抗血小板药物治疗;治疗组在对照组治疗基础上联合冠心通络胶囊治疗,连续治疗半年后观察两组患者中医证候疗效、心电图疗效及术后再狭窄发生率等指标。结果:疗程结束后,治疗组中医证候总有效率(85.3%)明显高于对照组(67.6%),两组比较,差异有统计学意义(P<0.05);治疗组心电图疗效总有效率为88.2%,显著高于对照组的70.6%,然其术后再狭窄发生率为5.9%,却明显低于对照组的11.8%,两组比较,差异均有统计学意义(P<0.05)。结论:冠心通络胶囊联合双联抗血小板药物防治冠心病患者PCI术后再狭窄临床疗效确切,可显著提高心电图疗效,降低术后再狭窄发生率。
Objective: To observe the clinical effect of Guanxin Tongluo Capsule combined with dual antiplatelet drugs in preventing and treating restenosis of coronary heart disease after PCI. Methods: Sixty-eight patients with coronary heart disease undergoing PCI under our hospital’s cardiology department were enrolled in this study. Patients were randomly divided into treatment group and control group, with 34 cases in each group. The control group was routinely combined with western medicine Antiplatelet drug treatment. The treatment group was treated with Guanxin Tongluo Capsule on the basis of the control group. After six months of continuous treatment, the curative effect of traditional Chinese medicine syndrome, electrocardiogram and the incidence of postoperative restenosis were observed. Results: After treatment, the total effective rate (85.3%) of the TCM syndromes in the treatment group was significantly higher than that in the control group (67.6%), the difference was statistically significant (P <0.05); the total effective rate (88.2%) was significantly higher than that of the control group (70.6%). However, the incidence of postoperative restenosis was 5.9%, which was significantly lower than that of the control group (11.8%). There was significant difference between the two groups (P <0.05) . Conclusion: Guanxin Tongluo Capsule combined with dual antiplatelet drugs in the prevention and treatment of coronary heart disease in patients with PCI restenosis clinical curative effect, can significantly improve the efficacy of electrocardiogram and reduce the incidence of postoperative restenosis.